Research – Development News Channel #beta #pharma


Posted On Aug 12 2017 by

#latest pharmaceutical news

#

Research Development News Channel

Antibody reduces harmful brain amyloid plaques in Alzheimer’s patients

Although the causes of Alzheimer’s disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons between ten and fifteen years before the emergence of initial clinical symptoms such as memory loss. Researchers have now been able to show that Aducanumab, a human monoclonal antibody, selectively binds brain amyloid plaques, thus enabling microglial cells to remove the plaques.

Last Updated: Saturday, 03 September 2016

Caffeine and its analogues revert memory deficits by normalizing stress responses in the brain

A study published in the journal Scientific Reports from Nature publishing group, describes the mechanism by which caffeine counteracts age-related cognitive deficits in animals. The study coordinated by Portuguese researchers from Instituto de Medicina Molecular (iMM Lisboa) and collaborators from Inserm in Lille, France, along with teams from Germany and United States,

Last Updated: Wednesday, 31 August 2016

Less efficacy than expected in largest drug-eluting stent trial

New generation drug eluting stents (new DES) did not outshine contemporary bare metal stents (BMS) as they were expected to, in a surprise finding of the largest randomized stent trial to date. The Norwegian Coronary Stent Trial (NorStent), presented at ESC Congress 2016, and published simultaneously in the New England Journal of Medicine, “demonstrates that the efficacy of new DES versus contemporary BMS is lower than expected,”

Last Updated: Wednesday, 31 August 2016

Vitamin C may boost effectiveness of acute myeloid leukemia treatment

A simple adjustment to patients’ therapeutic regimen may improve the effectiveness of the standard epigenetic treatment for myeloid dysplastic syndrome (MDS) and acute myeloid leukemia (AML). New findings published today in the Proceedings of the National Academy of Sciences showed in lab studies that supplementing an epigenetic cancer drug called decitabine with vitamin C enhanced the drug’s ability to

Last Updated: Tuesday, 30 August 2016

Discovery of a novel Wnt inhibitor with potential to eradicate colorectal cancer stem cells

A team including the National Cancer Center (NCC) (Tokyo, Japan), the RIKEN Center for Life Science Technologies (CLST) (Yokohama, Japan), and Carna Biosciences Inc. (Kobe, Japan) has jointly announced the development of a novel small-molecule Wnt inhibitor named NCB-0846. Wnt signaling is a key pathway of cancer stem cell (CSC) development.

Last Updated: Friday, 26 August 2016

Breast milk sugar may protect babies against deadly infection

A type of sugar found naturally in some women’s breast milk may protect new born babies from infection with a potentially life threatening bacterium called Group B streptococcus, according to a new study from Imperial College London. These bacteria are a common cause of meningitis in new borns and the leading cause of infection in the first three months of life in the UK and globally.

Last Updated: Friday, 26 August 2016

Finding new targets to treat vascular damage

Diabetes heightens the risk of vascular damage to heart and limbs, and impairs the ability to repair damage with new growth of blood vessels, called angiogenesis. There are no established drugs to improve angiogenesis in diabetes. However, researchers at Joslin Diabetes Center now have identified a gene called CITED2 in a molecular pathway that may offer targets for drugs that treat these conditions by strengthening angiogenesis.

Last Updated: Friday, 26 August 2016

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu.

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo.

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape.

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po.

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programm.

Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage sm.

Scientists at Florida Atlantic University’s Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale’s coast contains.

Diabetes heightens the risk of vascular damage to heart and limbs, and impairs the ability to repair damage with new growth of blood vessels, called angiogenesis. There a.

A type of sugar found naturally in some women’s breast milk may protect new born babies from infection with a potentially life threatening bacterium called Group B strept.

A team including the National Cancer Center (NCC) (Tokyo, Japan), the RIKEN Center for Life Science Technologies (CLST) (Yokohama, Japan), and Carna Biosciences Inc. (Kob.

An international team of researchers – led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni.

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical inve.





Last Updated on: August 11th, 2017 at 10:23 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *